Export 6 results:
Author Title [ Type(Desc)] Year
Filters: Author is Stadtmauer, Edward A  [Clear All Filters]
Journal Article
A. Krishnan, Pasquini, M. C., Logan, B., Stadtmauer, E. A., Vesole, D. H., Alyea, E., Antin, J. H., Comenzo, R., Goodman, S., Hari, P., Laport, G., Qazilbash, M. H., Rowley, S., Sahebi, F., Somlo, G., Vogl, D. T., Weisdorf, D., Ewell, M., Wu, J., Geller, N. L., Horowitz, M. M., Giralt, S., and Maloney, D. G., “Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial.”, Lancet Oncol, vol. 12, no. 13, pp. 1195-203, 2011.
E. A. Stadtmauer, Pasquini, M. C., Blackwell, B., Hari, P., Bashey, A., Devine, S., Efebera, Y., Ganguly, S., Gasparetto, C., Geller, N., Horowitz, M. M., Koreth, J., Knust, K., Landau, H., Brunstein, C., McCarthy, P., Nelson, C., Qazilbash, M. H., Shah, N., Vesole, D. H., Vij, R., Vogl, D. T., Giralt, S., Somlo, G., and Krishnan, A., “Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial.”, J Clin Oncol, vol. 37, no. 7, pp. 589-597, 2019.
C. A. Keever-Taylor, Devine, S. M., Soiffer, R. J., Mendizabal, A., Carter, S., Pasquini, M. C., Hari, P. N., Stein, A., Lazarus, H. M., Linker, C., Goldstein, S. C., Stadtmauer, E. A., and O'Reilly, R. J., “Characteristics of CliniMACS® System CD34-enriched T cell-depleted grafts in a multicenter trial for acute myeloid leukemia-Blood and Marrow Transplant Clinical Trials Network (BMT CTN) protocol 0303.”, Biol Blood Marrow Transplant, vol. 18, no. 5, pp. 690-7, 2012.
Q. Bashir, Nishihori, T., Pasquini, M. C., Martens, M. J., Wu, J., Alsina, M., Anasetti, C., Brunstein, C., Dawson, P., Efebera, Y., Gasparetto, C., Geller, N., Giralt, S., Hall, A. C., Koreth, J., McCarthy, P., Scott, E., Stadtmauer, E. A., Vesole, D. H., and Hari, P., “A Multicenter Phase II, Double-Blind, Placebo-Controlled Trial of Maintenance Ixazomib After Allogeneic Transplantation for High-Risk Multiple Myeloma: Results of the Blood and Marrow Transplant Clinical Trials Network 1302 Trial”, Transplant Cell Ther, vol. S2666-6367, no. 22, pp. 01467-1, 2022.
J. M. Vose, Carter, S., Burns, L. J., Ayala, E., Press, O. W., Moskowitz, C. H., Stadtmauer, E. A., Mineshi, S., Ambinder, R., Fenske, T., Horowitz, M., Fisher, R., and Tomblyn, M., “Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT C”, J Clin Oncol, vol. 31, no. 13, pp. 1662-8, 2013.
J. R. Wingard, Carter, S. L., Walsh, T. J., Kurtzberg, J., Small, T. N., Baden, L. R., Gersten, I. D., Mendizabal, A. M., Leather, H. L., Confer, D. L., Maziarz, R. T., Stadtmauer, E. A., Bolaños-Meade, J., Brown, J., Dipersio, J. F., Boeckh, M., and Marr, K. A., “Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation.”, Blood, vol. 116, no. 24, pp. 5111-8, 2010.